Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Somatostatin Receptor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT04888481
What this trial is testing

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Who this might be right for
Neuroendocrine Tumors
University of Alberta 600
Testing effectiveness (Phase 2)Looking for participantsNCT06607692
What this trial is testing

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Who this might be right for
Solid Tumor CancerMedulloblastomaHigh Risk Neuroblastoma+19 more
Fundación de investigación HM 25
Testing effectiveness (Phase 2)WithdrawnNCT04276597
What this trial is testing

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Who this might be right for
Pulmonary Neuroendocrine NeoplasmPheochromocytomaParaganglioma+7 more
Excel Diagnostics and Nuclear Oncology Center
Early research (Phase 1)Looking for participantsNCT05687123
What this trial is testing

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Who this might be right for
Metastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Looking for participantsNCT03206060
What this trial is testing

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Who this might be right for
PheochromocytomaParagangliomaNeuroendocrine Tumors+1 more
National Cancer Institute (NCI) 130
Testing effectiveness (Phase 2)Looking for participantsNCT06840821
What this trial is testing

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

Who this might be right for
Advanced Solid Tumors
Mainline Biosciences (Shanghai) Co., Ltd 156
Early research (Phase 1)WithdrawnNCT06411301
What this trial is testing

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

Who this might be right for
Multiple Myeloma, RefractoryMultiple Myeloma in RelapseMultiple Myeloma Progression
Jules Bordet Institute
Large-scale testing (Phase 3)Study completedNCT03673943
What this trial is testing

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Who this might be right for
Neuroendocrine Tumors
Radiomedix, Inc. 63
Not applicableActive Not RecruitingNCT03691064
What this trial is testing

Post-Authorization Long-Term Safety Study of LUTATHERA

Who this might be right for
Neuroendocrine Tumors
Advanced Accelerator Applications 1,014
Testing effectiveness (Phase 2)WithdrawnNCT04915144
What this trial is testing

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid Tumor+4 more
British Columbia Cancer Agency
Not applicableStudy completedNCT04946305
What this trial is testing

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Who this might be right for
Somatostatin Receptor-positive GEP-NET
Novartis Pharmaceuticals 89
Not applicableStudy completedNCT02389101
What this trial is testing

Molecular and Whole-body MR Imaging in Lymphomas

Who this might be right for
LymphomaHodgkin DiseaseLymphoma, Non-Hodgkin
Turku University Hospital 21
Early research (Phase 1)Study completedNCT04375267
What this trial is testing

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

Who this might be right for
Clinical Trial, Phase INeuroendocrine TumorsThymoma+1 more
Vastra Gotaland Region 18
Not applicableNot Yet RecruitingNCT06344832
What this trial is testing

SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs

Who this might be right for
Gastro-entero-pancreatic Neuroendocrine Tumor
Peking Union Medical College Hospital 40
Large-scale testing (Phase 3)Study completedNCT02685709
What this trial is testing

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

Who this might be right for
Acromegaly
Chiasma, Inc. 146
Not applicableStudy completedNCT05844332
What this trial is testing

LUTATHERA Injection General Use Result Survey

Who this might be right for
Somatostatin Receptor-positive Neuroendocrine Tumor
Novartis Pharmaceuticals 347
Not applicableActive Not RecruitingNCT02743741
What this trial is testing

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University Health Network, Toronto 195
Large-scale testing (Phase 3)Ended earlyNCT04837040
What this trial is testing

Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

Who this might be right for
Acromegaly
Crinetics Pharmaceuticals Inc. 58
Early research (Phase 1)Ended earlyNCT02359500
What this trial is testing

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Who this might be right for
Neuroendocrine TumorsCarcinoid Tumors
Lale Kostakoglu 71
Large-scale testing (Phase 3)Study completedNCT01578239
What this trial is testing

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Who this might be right for
Carcinoid Tumor of the Small BowelNeuroendocrine Tumour
Advanced Accelerator Applications 231
Next Page